mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) announced a strategic licensing agreement with Intas Pharmaceuticals Ltd, a multinational pharmaceutical company. Intas will hold the rights to commercialise Etanercept through its affiliates for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.
The agreement signifies mAbxience’s commitment to addressing the pressing need for innovative and affordable treatment options for autoimmune diseases. As per the press release, mAbxience will oversee the development, manufacturing, and supply of the biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP)-approved facilities.
“Expanding our global reach has always been at the core of mAbxience’s vision. Collaborating with Intas allows us to tap into new markets and bring our cutting-edge biosimilar candidate to countless patients battling autoimmune diseases. It reinforces our dedication to leading the way in the biosimilar industry,” said Jurgen Van Broeck, Global Commercial Director, mAbxience.
“Partnering up with mAbxience, who are known for their dedication to quality and innovation, aligns perfectly with our vision. The partnership enables us to achieve our goal of providing high-quality treatments to patients worldwide. Together, we aim to revolutionise the landscape of autoimmune disease treatment,” commented Intas’ Vice Chairman, Binish Chudgar.
